Do not take Tarceva (erlotinib) with food. It is important to take Tarceva one hour before or two hours after eating.
Tarceva Access Solutions provides coverage and reimbursement support, patient assistance and informational resources for both health care providers and their patients.
Watch four patients with NSCLC share their stories about taking Tarceva and living with this disease.
The topics in the Caregiver Support were created especially for you to help you learn about Tarceva basics, how to communicate with the patient and with others, ways to help ease the patient's daily life, and ways to care for yourself. You'll also find resource links and information on insurance coverage matters you may be helping to manage.
TARCEVA monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Results from two, multicenter, placebo-controlled, randomized, Phase III trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of TARCEVA with platinum-based chemotherapy [carboplatin and paclitaxel or gemcitabine and cisplatin] and its use is not recommended in that setting.
This site is intended for US residents only.
© 2008 Genentech USA, Inc. and OSI Pharmaceuticals, Inc. All rights reserved.
TARCEVA®, its logo mark and 
are trademarks of OSI Pharmaceuticals, Inc.
Patients & CaregiversTarceva for Advanced
|
Tarceva Access Solutions™ can help.
888-249-4918
